Leuven, Belgium, June 16, 2016 – TROD Medical NV, the medical device company developing tools for focal ablation announces completion of enrollment in its clinical study at two world-renown cancer research institutions, University College London (UCL) and New York University (NYU).
The clinical teams at NYU and UCL presented last month at the 111th American Urological Association’s Annual Meeting (San Diego, CA), on patients treated with Encage. Together with a study running at the Moffitt Cancer Center (Tampa, Florida), over 40 patients have now been treated using Encage. Results not yet published show total tissue destruction in target ablation zones and very significant reduction of side effect (erectile dysfunction and urinary incontinence rates down to 0%).
Prof. Mark Emberton from UCL said: “The wonderful thing about Encage is its simplicity. It uses an energy source that clinicians are familiar with and provides very controlled and predictable tissue destruction. It is also extremely versatile in that it can be used to treat small prostate cancers with precision but can also be used to treat the prostate in a zonal manner.”
“Encage is a disruptive technology with the potential to maximize target ablation zones in the prostate while minimizing the all too common side effects associated with current treatments” said Andre Faure, CEO of TROD Medical. He continued, “This significant clinical work at prestigious US and UK institutions builds on the CE Mark Approval for Encage obtained in January 2016, and US FDA 510(k) clearance secured in 2008, and has led to significant attention from major strategic players in urology and surgical oncology.”
TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.
Trod Medical will be attending the NYU Symposium on Advances in Prostate Imaging, Detection and Ablative Treatment of Prostate Cancer on 17-18 June in New York City.
Notes to Editor
TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.
Trod Medical’s proprietary product, Encage, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.
TROD Medical is a private venture-backed company with headquarters in Leuven (Belgium) and facilities in the Tampa Bay area (USA), and Paris (France).
Issued for and on behalf of Trod Medical by Instinctif Partners.
For more information please contact: email@example.com